Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

Subcutaneous allergen immunotherapy (SCIT) with aeroallergens is covered for allergic rhinitis, allergic conjunctivitis, allergic asthma, combined respiratory allergy, and dust-mite–related atopic dermatitis (after 90 days failed therapy) when there is a clinically relevant allergic component (symptoms on natural exposure or consistent temporal pattern) and demonstrable specific IgE. Coverage requires documented prior pharmacologic/environmental management (or other qualifying reasons), physician preparation/plan, administration under trained supervision in a facility equipped for anaphylaxis, periodic evaluations every 6–12 months, and an initial maintenance course typically of 3–5 years; SCIT is excluded in pregnancy, for food sensitivities, SLIT, absence of specific IgE, and as first-line therapy without prior treatment.

"SCIT using aeroallergen preparations is reasonable and necessary for allergic rhinitis and/or allergic conjunctivitis (seasonal, perennial, or both)."